Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00354341 |
This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Condition | Intervention | Phase |
---|---|---|
Anemia |
Drug: epoetin beta [NeoRecormon] |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open-Label Study of the Effect of Anemia Correction With NeoRecormon on Cardiac Structure and Function in Anemic Patients With Early Diabetic Nephropathy. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Ebenhard Ritz, Prof. Dr. | unaffliated |
Study ID Numbers: | MA16620 |
Study First Received: | July 19, 2006 |
Last Updated: | July 19, 2006 |
ClinicalTrials.gov Identifier: | NCT00354341 |
Health Authority: | Italy: Ministry of Health |
Epoetin Alfa Diabetic Nephropathies Urologic Diseases Hematologic Diseases Diabetes Mellitus |
Anemia Endocrine System Diseases Endocrinopathy Kidney Diseases Diabetes Complications |